REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Completed · Phase 2

Conditions studied: Neurotrophic Keratitis

In brief

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.

Key facts

Study ID: NCT04276558
Run by: RECORDATI GROUP
People needed: 108
Starts: 2020-10-13
Expected to finish: 2024-04-29
Last updated by the study team: 2025-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have read, understood, and signed the informed consent form (ICF).
Be a male or female aged ≥18 years at the time of ICF signature.
Have stage 2 moderate (PED) or stage 3 severe (corneal ulcer) NK involving only 1 eye (study eye) and of at least 2 weeks duration. Patients with Stage 1 NK in the fellow eye can be enrolled.
for the study eye
Have no objective clinical evidence of improvement in the PED or corneal ulceration within the 2 weeks before the screening visit despite use of conventional non-surgical treatment (eg, nonpreserved ocular lubricants, nonpreserved topical antibiotics, oral doxycycline, patching, serum tears, and/or therapeutic contact lenses) as determined by the investigator's or referring physician's medical record.
Have decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.
Have a BCDVA score ≤ 75 ETDRS letters in the study eye, due to NK.

You may not qualify if…

Have participated in any clinical trial with an investigational drug/device within 2 months before the Screening Visit and throughout the study duration.
Have a known hypersensitivity to one of the components of the study drug or procedural medications (eg, fluorescein), including to a compound chemically related to MT8
Have a presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (eg, progressive or degenerative corneal or retinal conditions, lagophthalmos, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases), or that may compromise the safety of the patient.
Have a significant history of alcohol abuse or drug/solvent abuse
Be unwilling to comply with any study assessments or procedures.
Be a woman who is pregnant, nursing or planning a pregnancy.
Be a woman of childbearing potential not using a highly effective method of birth control.
Be a male patient who is not permanently sterile and who is not willing to use condoms during the study and for 4 weeks after the end of study treatment.
For the study eye:
Have any active ocular infection (bacterial, viral, fungal or protozoal) or active inflammation not related to NK in the study eye.
Have any other ocular disease requiring topical ocular treatment in the study eye during the course of the study treatment period, except for glaucoma if treated by preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study),
Receive topical ophthalmological treatments other than the study drug provided by the study Sponsor and the treatments allowed by the study protocol (eg, preservative-free artificial tears; preservative-free eye drop (single-agent treatment, once daily, stable regimen 4 weeks before screening and during the study) for glaucoma; topical antibiotics; other than tetracycline).
Have severe blepharitis and/or severe meibomian gland disease in the study eye.
Have severe vision loss in the study eye with no potential for visual improvement in the opinion of the investigator as a result of the study treatment.
Have evidence of corneal ulceration/melting involving the posterior third of the corneal stroma, or perforation in the study eye.
Have a history of any ocular surgery (including laser or refractive surgical procedures) within 3 months before the Screening Visit in the study eye. An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the Stage 2 or 3 NK.
Have a history of corneal transplantation in the study eye, except if performed to treat NK and at least 6 months prior screening.
Have had prior surgical procedures for the treatment of NK (eg, tarsorrhaphy, conjunctival flap, etc.) except AMT, if at least 2 wks after the membrane has disappeared within the area of the PED or corneal ulcer (and at least 6 weeks after the procedure) in the study eye.
Use therapeutic contact lenses or wear contact lenses for refractive correction during the study treatment periods in the eye(s) with NK.
Have an anticipated need for punctal occlusion during the study treatment period. Patients with punctal occlusion or punctal plugs inserted before the study are eligible for enrolment provided that the punctal occlusion is maintained during the study.
Have an uncontrolled glaucoma at the Screening Visit. (Patients suffering from glaucoma requiring ophthalmic drops for topical treatment at the Screening Visit or during the study are not eligible, except if the ophthalmic drops is a preservative-free treatment administered maximum once daily as a single-agent treatment and at a stable regimen 4 weeks before screening and at the same dose during the study. Patients treated with oral intraocular pressure-lowering drugs at the Screening Visit and during the study may be enrolled if their glaucoma status is assessed as stable and controlled.
For the fellow eye
Have Stage 2 or 3 NK or perforation.
For any eye:
Have a history of ocular cancer.

Where it is running

Nature Coast Clinical Research — Crystal River, Florida, United States
University of Florida — Gainesville, Florida, United States
University of Maryland School of Medicine UMSOM — Baltimore, Maryland, United States
University of Michigan - Kellogg Eye Center — Ann Arbor, Michigan, United States
Mt. Sinai New York Eye and Ear Infirmary — New York, New York, United States
Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States
Toyos Clinic — Nashville, Tennessee, United States
Houston Eye Associates HEA - Gramercy Location — Houston, Texas, United States
University of Wisconsin-Madison — Madison, Wisconsin, United States
Dijon University Hospital CHU Dijon — Dijon, France
CHU Paris Centre - Hôpital Cochin — Paris, France
Hôpital Fondation Adolphe de Rothschild — Paris, France
Hôpital Universitaire Necker — Paris, France
Ludwig-Maximilians-Universitaet Muenchen LMU - Augenklinik — Munich, Bavaria, Germany
Uniklinik Koeln — Cologne, Germany
Hospital Eye University of Duesseldorf — Düsseldorf, Germany
Universitaetsklinikum Frankfurt — Frankfurt, Germany
Saarland University Medical Center — Homburg, Germany
UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz — Mainz, Germany
Markusovszky University Teaching Hospital — Szombathely, Vas County, Hungary
Semmelweis University, Dept. of Ophthalmology — Budapest, Hungary
University of Pecs - Dpt of Ophthalmology — Pécs, Hungary
Università Magna Grecia di Catanzaro — Germaneto, Calabria, Italy
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari Clinica Oculistica — Bari, Italy
DIMES Universit di Bologna — Bologna, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.